ライフサイエンスコーパス: myalgia

1 had more general symptoms (fever, asthenia, myalgia).

2 ritis and sometimes prolonged arthralgia and myalgia.

3 ts were fatigue, rash, diarrhea, nausea, and myalgia.

4 liver function test elevation, fatigue, and myalgia.

5 stemic reactions were headache, malaise, and myalgia.

6 therapeutic index relative to statin-induced myalgia.

7 ctions included mild to moderate malaise and myalgia.

8 adverse events were bone pain, headache, and myalgia.

9 ausea and emesis, neuropathy, and arthralgia/myalgia.

10 ers, leukocytosis, skin rash, arthralgia and myalgia.

11 cterized by fever, rash, polyarthralgia, and myalgia.

12 g injection-site pain, malaise, headache, or myalgia.

13 e tested the association of the variant with myalgia.

14 central pain processing in reserpine induced myalgia.

15 e a potential analgesic therapy for ischemic myalgia.

16 pital with a persistent fever, headache, and myalgia.

17 iruses cause debilitating polyarthralgia and myalgia.

18 sarcopaenic and at increased risk of statin myalgia.

19 and fatigue and one developed arthralgia and myalgia.

20 ology as opposed to being arthralgias and/or myalgias.

21 bo, LPS caused headache, nausea, chills, and myalgias.

22 atistically significant (p < .05) except for myalgias.

23 on (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depres

24 The most frequent symptoms reported were myalgia (100%), fatigue (91%), fever (82%), headache (59

25 events were fatigue (29%), nausea (12%), and myalgia (11%).

26 559 [32.8%] of 1705 participants, P < .001; myalgia: 115 [26.6%] of 432 vs 580 [34.0%] of 1705 parti

27 ogic toxicities included neuropathies (26%), myalgia (13%), and fatigue (10%).

28 headache (17 [43%] of 40 participants), and myalgia (14 [35%] of 40 participants) most commonly repo

29 were nasal congestion (16% of patients) and myalgia (14%).

30 20.4%), altered consciousness (20.9%; 6.8%), myalgia (16.9%; 7.6%), dysgeusia (7.4%; 1.9%), anosmia (

31 atorvastatin than placebo subjects developed myalgia (19 versus 10; P=0.05).

32 Both vaccines were well-tolerated, with myalgia (19%), malaise (14%), and local pain (10%) the m

33 constipation (31 [36%]), fatigue (29 [33%]), myalgia 21 [24%]), and peripheral oedema 20 [23%]).

34 iarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]).

35 o [95% confidence interval], 4.6 [3.1-6.8]), myalgia (3.0 [2.2-4.0]), cough (2.7 [1.9-3.9]), and chil

36 6, 95% confidence interval [CI] = 3.1, 6.8), myalgia (3.0, 95% CI: 2.2, 4.0), cough (2.7, 95% CI: 1.9

37 Among 59 symptomatic participants, myalgias (30 [50.8%]), chills (27 [45.8%]), weakness (23

38 e rash included fever (62%), lethargy (41%), myalgia (31%), and headache (27%); lymphadenopathy was a

39 fever (62%-72%), lymphadenopathy (56%-86%), myalgias (31%-55%), malaise (23%-57%), and headache (25%

40 (45 patients [63%] vs 18 patients [42%]) and myalgias (32 patients [44%] vs 9 patients [21%]).

41 d included fever (85%), chills/sweats (54%), myalgias (38%), fatigue (31%), nausea/vomiting (31%), he

42 ucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%).

43 ptoms included fever (48.2%), cough (41.2%), myalgia (41.2%), and fatigue (40%).

44 sms (13% v 1%), neutropenia (29% v 18%), and myalgia (5% v 0%).

45 of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs.

46 tions, including fever (96%), malaise (88%), myalgia (57%), cough (25%), and dizziness (14%).

47 stomatitis (9%), neurosensory changes (7%), myalgia (7%), and diarrhea (7%).

48 e most frequent symptom (80.5%), followed by myalgia (70.7%), sore throat (63.4%), and fever (58.5%).

49 rol 70.4 +/- 0.7 years) and nine with statin myalgia (71.5 +/- 0.9 years).

50 ry neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (6%).

51 s (8%; three patients on seladelpar 200 mg), myalgia (8%; one patient on placebo and two on seladelpa

52 l features at presentation were fever (87%), myalgia (83%), skin (88%), renal (19%), severe gastroint

53 severe epidemics among ruminants and fever, myalgia, a hemorrhagic syndrome, and/or encephalitis in

54 o more likely to have a headache, dizziness, myalgias, abdominal pain, anorexia, leukopenia, lymphope

55 Myalgia (adjusted odds ratio [OR], 4.04; P = .02), hemor

56 be extended to patients with longer onset of myalgia after statin initiation.

57 One patient experienced grade 3 myalgia after tracer injection.

58 h a systemic illness that includes fever and myalgia and a characteristic rash, with papules that evo

59 biopsy obtained from a patient with chronic myalgia and arthralgia 6 months after acute SINV infecti

60 scle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal.

61 nose, sore throat, difficulty breathing, or myalgia and collected data on other symptoms and nasal s

62 ose was associated with a lower incidence of myalgia and gastrointestinal (GI) disturbances than that

63 to distinguish from other conditions causing myalgia and may often lead to statin discontinuation.

64 years; other features included a history of myalgia and muscle cramps.

65 Statins are associated with muscle myalgia and myopathy, which probably reduce habitual phy

66 grade 3 adverse events: one patient (2%) had myalgia and one patient (2%) had general physical health

67 eekly visual analogue scale (VAS) scores for myalgia and specific symptoms (VAS myalgia score and sym

68 The acute presentation was with malaise, myalgia and weakness, nausea and vomiting, and tender he

69 ases were defined as persons presenting with myalgia and/or periorbital edema and Trichinella-specifi

70 Myalgias and arthralgias of grades 1 to 2 occurred in 16

71 th NAGU exhibit nonspecific symptoms such as myalgias and fever, suggesting an infectious agent, but

72 One patient had myalgias and malaise after the first infliximab infusion

73 ient had a "flulike" illness associated with myalgias and malaise.

74 Myalgias and oral stomatitis were reported less frequent

75 (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chroni

76 rare event, most recent studies suggest that myalgias and relatively low-level muscle damage may occu

77 stemic reactions (eg, fatigue, headache, and myalgia) and health impacts reported by v-safe responden

78 higher proportions of arthralgia, weakness, myalgia, and age 41-60 years.

79 ile categories except fluid retention, rash, myalgia, and anemia, which were more common at higher im

80 A febrile syndrome with fatigue, headache, myalgia, and arthralgia was highly associated with serop

81 teristic symptoms, including cutaneous rash, myalgia, and arthralgia, with the latter sometimes persi

82 Ts were neutropenia, stomatitis/pharyngitis, myalgia, and arthralgia.

83 me, diarrhea, hyperbilirubinemia, skin rash, myalgia, and arthralgia.

84 iated with fever, chills, headache, fatigue, myalgia, and arthralgia.

85 symptoms, including fever, headache, chills, myalgia, and arthralgia.

86 ents receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain.

87 rted grade 3 systemic symptoms were fatigue, myalgia, and chills.

88 y nose, sore throat, difficulty breathing or myalgia, and collected data on other symptoms and nasal

89 eutropenia, fatigue, neuropathy, arthralgia, myalgia, and diarrhea.

90 luding rash, arthralgia, headache, pruritus, myalgia, and fever.

91 clinical presentations were fever, weakness, myalgia, and gastrointestinal symptoms.

92 obesity, more frequently reported fever and myalgia, and had lower D-dimer levels compared to White

93 be obese, more frequently reported fever and myalgia, and had lower D-dimer levels compared with whit

94 rees F), cough, upper respiratory infection, myalgia, and headache were reported.

95 se events were injection-site pain, fatigue, myalgia, and headache.

96 endocrine dysregulation, fatigue, dysphoria, myalgia, and impaired mental and physical performance.

97 ause reactogenic side effects such as fever, myalgia, and injection site pain that have reduced their

98 cited adverse events were fatigue, headache, myalgia, and injection-site pain.

99 bserved systemic AEs were mostly headache or myalgia, and local AEs were application-site reactions,

100 ther tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included five (15.6%) patients

101 icipants included fatigue, chills, headache, myalgia, and pain at the injection site.

102 equently included fatigue, chills, headache, myalgia, and pain at the injection site.

103 resented with acute renal failure, weakness, myalgia, and pigmented urine.

104 eded admission with a sore throat, headache, myalgia, and pyrexia.

105 iorated LPS-induced fever, chills, headache, myalgia, and tachycardia (P<.01).

106 more likely to report sore throat, headache, myalgia, and taste or smell loss.

107 at is characterized by high fever, headache, myalgia, and vomiting.

108 quiring statin treatment, who develop statin myalgia, and who cannot be satisfactorily treated with o

109 rred in 99 subjects (54 discontinuations, 49 myalgias, and 9 CK elevations).

110 nstitutional symptoms consisting of malaise, myalgias, and anorexia were the dose-limiting toxicities

111 nspecific prodrome of weakness, fatigue, and myalgias, and are at risk for ischemia-induced organ fai

112 as well tolerated with only low-grade fever, myalgias, and fatigue reported and 2 patients experienci

113 presented with 2 to 21 d of dyspnea, cough, myalgias, and fever.

114 olerated, with injection site pain, malaise, myalgias, and headache being the most frequently reporte

115 His illness onset included malaise, myalgias, and low-grade fever.

116 ring loss, febrile neutropenia, hypotension, myalgias, and skin rash and were removed from treatment

117 ommonly either musculoskeletal (arthralgias, myalgias, and weakness) or pulmonary (cough, dyspnea, an

118 However, myalgias are much more common and limit their use in man

119 other non-specific symptoms (fever, malaise, myalgia, arthralgia and disturbances of smell or taste).

120 FQs were associated with tendinopathy, myalgia, arthralgia, and nausea.

121 ore common with combination therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were m

122 ptoms, including fever, headache, skin rash, myalgia, arthralgia, depression, and coma.

123 More myalgia, arthralgia, edema, and febrile neutropenia occu

124 orted from exposed patients were: neck pain, myalgia, arthralgia, paresthesia, sleep disorder, poor a

125 orted from exposed patients were: neck pain, myalgia, arthralgia, paresthesia, sleep disorder, poor a

126 t least two of headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations,

127 ory difficulty (2.2-fold), cough (2.2-fold), myalgia/arthralgia (2-fold), and diarrhea (1.4-fold) as

128 (14%), diarrhea (11%), nausea/vomiting (5%), myalgia/arthralgia (3%), and sensory neuropathy (3%).

129 ne grade 3 hypertriglyceridemia, two grade 3 myalgia/arthralgia, and one grade 3 fatigue.

130 The most frequent toxicities were myalgia/arthralgia, fatigue, and triglyceridemia.

131 istration and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%),

132 3.2, P = .16), they were less likely to have myalgias/arthralgias (P< .001) and vomiting (P = .02).

133 e degree of grade 2 constitutional symptoms (myalgias/arthralgias and fatigue) at 75 micrograms/kg, d

134 Grade III myalgias/arthralgias and headaches required dose reducti

135 Reversible grade 2 fatigue and myalgias/arthralgias were seen in all pts at 75 microgra

136 symptoms (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hy

137 Fever, myalgias/arthralgias, fatigue, nausea, and headaches wer

138 report anorexia, asthenia, diarrhea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at a

139 toxicities, such as cheilitis, headache, and myalgias/arthralgias, were mild or absent.

140 Myalgias at doses 0.2 mg/kg or greater were dose limitin

141 onditions), as were those reporting fever or myalgias at presentation (P = .002, vs. P = .005 without

142 cterized by fever with chills, headache, and myalgias at the highest dose.

143 headache, malaise, fatigue, arthralgias, and myalgias) before randomization.

144 The principal toxicities were myalgias, bone pain, fever, nausea, and mild thrombocyto

145 common symptom was fever, followed by cough, myalgia, chills, and fatigue.

146 n among nonpregnant women, whereas headache, myalgia, chills, and fever were reported less frequently

147 least 37.6 degrees C, and most had headache, myalgias, chills, and varying combinations of leukopenia

148 x disease, malaise or fatigue, joint pain or myalgias, constipation, insomnia, polyuria, weakness, ab

149 illness episodes with >=1 of the following: myalgia, cough, runny nose/nasal congestion, sore throat

150 including fever >/=37.8 degrees C, headache, myalgia, cough, sore throat, runny nose and sputum), pau

151 eletal muscle, causing exercise intolerance, myalgia, cramps, or fixed weakness, which often affects

152 were not different than control in terms of myalgia, creatine kinase elevation, cancer, and disconti

153 n monotherapy versus placebo; and reports of myalgia, creatine kinase elevations, rhabdomyolysis, tra

154 risk of transaminase elevations, but not of myalgias, creatine kinase elevations, rhabdomyolysis, or

155 CFA and Col produced distinct myalgia development trajectories.

156 2.86 vs 3.63 KPa and MEP: 2.93 vs 4.63 KPa), myalgia disappeared (VAS dropped from 6 to 0), and quali

157 matous, macular rash that, together with the myalgia, displays centrifugal migration.

158 for treatment-associated arthralgias and/or myalgias during 17 of 52 treatment courses.

159 dverse events include generalised oedema and myalgia (each in two [1%] patients) in those given pembr

160 1 were minimal; the most common were nausea, myalgias, edema, and diarrhea.

161 nts being fatigue (14 [30%]; all grade 1-2), myalgia (eight [17%]; all grade 1-2), and peripheral oed

162 setting adverse events, such as an excess of myalgias, elevation of hepatic aminotransferases levels

163 ical manifestations including polyserositis, myalgia, epididymitis, and hearing loss weeks to months

164 Other clinical features included headache, myalgia, epididymo-orchitis, urinary retention, hemateme

165 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash.

166 ne (2%) grade 3 syncope and one (2%) grade 3 myalgia event in different cohorts.

167 These results suggest that the myalgia experienced by individuals with TRAPS is due to

168 s with symptoms of fibromyalgia (arthralgia, myalgia, fatigue) and oral and ocular dryness in the pre

169 ogy characterized by episodes of angioedema, myalgia, fatigue, and fever that occur every 3 to 8 week

170 ts develop a syndrome of diffuse arthralgia, myalgia, fatigue, and subjective cognitive difficulty du

171 (grade 4) toxicities including neutropenia, myalgia, fatigue, depression, and other neurologic toxic

172 Cough, fever, shortness of breath, myalgia, fatigue/weakness and headache also decreased af

173 gs was not possible, but fever and prominent myalgias favored influenza and prominent rhinorrhea favo

174 Side effects of interferon therapy include myalgias, fever, nausea, irritability, and depression.

175 with symptoms including fever, headache, and myalgia, followed by swelling of the salivary glands.

176 l presentations were characterised by fever, myalgia, headache, and confusion, followed by severe mul

177 uding cough, chills, fever, nausea, fatigue, myalgia, headache, and diarrhea, as well as smell and ta

178 Myalgia, headache, and fatigue were common.

179 0, and 50/50 groups, respectively; transient myalgia, headache, and fatigue were the commonest system

180 Fatigue, myalgia, headache, and injection site pain were the most

181 Common side effects included fatigue, myalgia, headache, arthralgia and fever.

182 Common side effects included fatigue, myalgia, headache, arthralgia, and fever.

183 iratory airways leading to dry cough, fever, myalgia, headache, fatigue, and diarrhea and can end up

184 s presenting with acute febrile illness with myalgia, headache, neutropenia, thrombocytopenia, and el

185 degrees C, hypotension, rigors, arthralgias, myalgias, headache, and/or malaise.

186 is acute febrile illness is characterized by myalgias, headache, thrombocytopenia, and elevated serum

187 ue (HR, 2.32; 95% CI, 1.18-4.55; P = 0.014), myalgia (HR, 1.48; 95% CI, 1.03-2.15; P = 0.036) during

188 ld proximal weakness in 3 of 8, and isolated myalgia in 1 of 8, followed by development of diffuse ri

189 alaise in 13 (46%), dizziness in nine (32%), myalgia in four (14%), and chills in four (14%).

190 ive outbreaks of debilitating arthralgia and myalgia in human populations.

191 g monacolin K taken per day is minimal (mild myalgia in previously severely statin-intolerant subject

192 rates of transient local injection pain and myalgia in the 4CMenB group.

193 g intravenous administration were malaise or myalgia in three (18%) participants and headache or chil

194 e of vague symptoms of dryness, fatigue, and myalgias in the general population.

195 including cough (in four of nine patients), myalgia (in three), sore throat (in two), and malaise (i

196 systemic reactions (chills, arthralgias, and myalgias) in the vaccine group than in the placebo group

197 Myalgia, increased levels of creatine kinase, and persis

198 Markers of myalgia (intrusive body pain) and myopathy (self-reporte

199 Statin-related myalgia is difficult to distinguish from other condition

200 Myalgia is one of the most characteristic features of th

201 et over 3-7 days with malaise, headache, and myalgia is typical.

202 Clinical findings include fever, headache, myalgia, leukopenia, thrombocytopenia, and hepatic infla

203 n of both ehrlichioses with fever, headache, myalgias, leukopenia, thrombocytopenia, and elevated liv

204 Statins had little or no effect on cancer, myalgia, liver function, or withdrawal from treatment, a

205 symptoms (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizziness, metalli

206 SAMS is the most frequent SAS, and mild myalgia may affect 5% to 10% of statin users.

207 ong-term sequelae such as fatigue, weakness, myalgia, memory loss, and depression.

208 Rates of myalgia, muscle weakness, neuropsychiatric conditions, c

209 The presenting clinical features are myalgias, myoglobinuria, and an elevated serum creatine

210 Adverse events reported included myalgia (n = 2), elevation in the creatine kinase level

211 multiple symptoms with minimal arthralgia or myalgia (n = 4, n = 14).

212 l illness (n = 54), fever (n = 47), and limb myalgia (n = 41).

213 (n = 88 [62.0%]), fatigue (n = 78 [54.9%]), myalgia (n = 69 [48.6%]), nausea (n = 65 [45.8%]), palma

214 = 1), nausea (n = 1), vomiting (n = 1), and myalgias (n = 1).

215 edema, n = 7; conjunctival injection, n = 7; myalgia, n = 1; all grade 1).

216 se events included fatigue, fever, headache, myalgia, nausea, and decreased appetite.

217 penia and leukopenia followed by neuropathy, myalgia, nausea, fatigue, headache, arthralgia, and vomi

218 atory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, an

219 he low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatm

220 = 3 neuropathy, neutropenia, arthralgia, and myalgia occurred in the nab-PC arm, and less thrombocyto

221 The variant was not associated with myalgia (odds ratio, 0.84; 95% confidence interval, 0.52

222 p; one patient had recurrence of fatigue and myalgia one year after CTL infusion.

223 (one [2%] person in the placebo group), and myalgia (one [2%] person in each group).

224 adverse events occurred in one patient each: myalgia (one [2%]), increased blast cell count (one [2%]

225 sented with such symptoms as fever (94%) and myalgia or arthralgia (78%).

226 icity included peripheral neuropathy in 57%, myalgia or arthralgia in 30%, neutropenia in 53%, neutro

227 EC-D reported significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and pe

228 ith high fever, chills, marked headache, and myalgia or arthralgia.

229 Progression of myalgia or myositis to rhabdomyolysis is rare (one in 30

230 mptom attributable to malaria, with fatigue, myalgias or arthralgias, headache, and chills most commo

231 of the muscle disorder may vary from trivial myalgias or elevations of creatine kinase in asymptomati

232 Chronic myalgias or other pain syndromes have not been confirmed

233 CAE) as discontinuation for any side effect, myalgia, or CK >3x upper limit of normal during follow-u

234 fever, headache, neck stiffness, arthralgia, myalgia, or fatigue.

235 headache, elevated temperature, arthralgias, myalgias, or fatigue, a larger number of macrophages and

236 everity showed a significant amelioration of myalgia (P = .003), headache (P = .025), and fatigue (P

237 Subjective fever (p<0.0001), myalgia (p=0.036), and chills (p=0.026) were significant

238 exposed individuals characterized by fever, myalgia, periorbital edema, and fatigue.

239 x disease, malaise or fatigue, joint pain or myalgias, polyuria, weakness, abdominal pain, and headac

240 Bone pain, myalgia, presyncope, or fever occurred in 55% of patient

241 .8), history of eczema (mOR=3.4), fever with myalgia prior to illness (mOR=2.6), having tonsils (mOR=

242 A 67-year-old woman had fever, myalgias, progressive weakness, and respiratory insuffic

243 AEs, particularly fever, myalgias, pruritus, and proteinuria/hematuria, occurred

244 tly symptomatic infections, marked by fever, myalgia, rash and polyarthralgia that can last for up to

245 mans characterized by fever, polyarthralgia, myalgia, rash, and headache.

246 Fever, myalgia, rash, night sweats, and arthralgia occurred mor

247 s by which ischemic-like conditions generate myalgia remain unclear.

248 The reserpine-induced myalgia (RIM) model lowers pain thresholds and produces

249 n significant absolute increases in risks of myalgias (risk difference/1000 patients [RD], 2.7; 95% C

250 se events (RR, 0.99 [95% CI, 0.94 to 1.04]), myalgias (RR, 0.96 [95% CI, 0.79 to 1.16]), or liver-rel

251 The primary outcome was the VAS myalgia score (range, 0 to 100 mm).

252 cores for myalgia and specific symptoms (VAS myalgia score and symptom-specific VAS score, respective

253 e seen between statin and placebo in the VAS myalgia score, symptom-specific VAS score, pain interfer

254 Symptoms included headache, fever, chills, myalgia, shortness of breath, and fatigue.

255 s (fever, anorexia, weight loss, fatigue and myalgias), signs of systemic inflammation (anemia, throm

256 s of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; some patients

257 er/feverish, cough, congestion, pharyngitis, myalgias), staff obtained a mid-turbinate nasal swab in

258 lack of association between the variant and myalgia suggests that it cannot reliably be used as a bi

259 Eosinophilia-myalgia syndrome (EMS) is characterized by subacute onse

260 eosinophilic conditions such as eosinophilia-myalgia syndrome and idiopathic hypereosinophilic syndro

261 s, toxic oil syndrome in Spain, eosinophilia-myalgia syndrome from contaminated L-tryptophan, diethyl

262 neuropathy, are uncommon, and the arthralgia/myalgia syndrome was not observed.

263 r, these conditions include the eosinophilia-myalgia syndrome, epidemic toxic oil syndrome, eosinophi

264 ; and "isolated" polymyalgia rheumatica with myalgias, systemic inflammation, and subclinical vasculi

265 5 [22%] of 67 patients), fatigue (14 [21%]), myalgia (ten [15%]), arthralgia (nine [13%]), and diarrh

266 ts had significantly higher presentations of myalgia than in children.

267 er is characterized by severe arthralgia and myalgia that can persist for years and have considerable

268 7% of patients may experience statin-induced myalgia that limits compliance with a treatment regimen.

269 keletal and respiratory muscle weakness, and myalgia that negatively affected her quality of life.

270 strointestinal symptoms, chills, joint pain, myalgia, thrombocytopenia, leukocytopenia, and some hemo

271 h myotoxicity, which ranges in severity from myalgias to rhabdomyolysis resulting in renal failure an

272 ve myotoxic effects ranging in severity from myalgias to rhabdomyolysis.

273 nalyses, fluid retention, superficial edema, myalgia, vomiting, and rash were less frequent with dasa

274 Statin myalgia was associated with impaired muscle function, in

275 n multivariate logistic regression analysis, myalgia was less likely with HCoV infection than with LD

276 Myalgia was studied in JUPITER trial participants.

277 Generalized myalgia was the DLT.

278 Generalized myalgia was the dose-limiting toxicity (DLT) and occurre

279 Myalgia was the most common treatment-emergent adverse e

280 Myalgia was the only symptom that differed between group

281 n these 4 (measured fever, cough, chills, or myalgia) was 95% sensitive and 27% specific.

282 these four (measured fever, cough, chills or myalgia), was 95% sensitive and 27% specific.

283 Thrombocytopenia, neuropathy, and myalgia were greater with paclitaxel 250 mg/m2 (P <.05).

284 f 116 participants, P = .003), and fever and myalgia were less common among participants who had rece

285 Arthralgia, arthritis, edema, and myalgia were more common in adults compared to children.

286 Fever, arthralgia, and myalgia were more common in older children (12-17 years)

287 Arthralgias and myalgia were reported significantly more often by conval

288 Injection-site pain, fatigue, headache, and myalgia were the most common ARs.

289 Headache, fatigue, and myalgia were the most commonly reported solicited system

290 Administration site pain and myalgia were the most frequently reported in both groups

291 Anosmia, fever, and myalgia were the only symptoms associated with HCW SARS-

292 Myalgias were dose-related and cumulative, and often sta

293 At 8-month follow-up, fatigue, headache, and myalgias were persistent symptoms; gait and movement dis

294 ed patients with a history of statin-related myalgia whose symptoms are difficult to evaluate, n-of-1

295 mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weak

296 ave abrupt onset of respiratory symptoms and myalgia with or without fever and recover within 1 week,

297 itis, AQP4-IgG seropositivity, and recurrent myalgias with hyperCKemia.

298 g travelers returning ill from Malaysia with myalgia, with or without fever, should consider AMS, not

299 e statin that was previously associated with myalgia within 3 weeks of open-label use versus matching

300 We hypothesised that statin myalgia would be allied to impaired strength and work ca